Atlas Trials

Study of Safety and Efficacy of KTE-C19 in Combination With Atezolizumab in Adults With Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

Clinical trial NCT02926833 · COMPLETED

Trial details

NCT number
NCT02926833
Sponsor
Kite, A Gilead Company
Status
COMPLETED
Phase
Phase 1, Phase 2
Study type
INTERVENTIONAL
Refractory Diffuse Large B Cell Lymphoma
Start date
2016-09-29
Primary completion
2023-01-12
Enrollment
37

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.